DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Fludarabine
Fludarabine
Fludarabine Phosphate Powder for Solution for Injection Or Infusion
Fludarabine Phosphate (NSC 312878) Infusions for the Treatment of Acute Leukemia: Phase I and Neuropathological Study1
Fludarabine-Based Versus Chop-Like Regimens with Or Without Rituximab in Patients with Previously Untreated Indolent Lymphoma
©Ferrata Storti Foundation
Immune Recovery After Fludarabine–Cyclophosphamide
Prodrugs: a Challenge for the Drug Development
Sorafenib and Omacetaxine Mepesuccinate As a Safe and Effective Treatment for Acute Myeloid Leukemia Carrying Internal Tandem Du
Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia
FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: an Observational Study
Package Leaflet: Information for the User Fludarabine Phosphate 25 Mg/Ml Concentrate for Solution for Injection Or Infusion Fludarabine Phosphate
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
Powerpoint Sunusu
Cyclophosphamide-Fludarabine IV (3 Day) Ver
Acute Myeloid Leukemia (AML) Treatment Regimens
Chronic Myelogenous Leukemia (CML) Agents – Unified Formulary
Cancer Drug Costs for a Month of Treatment at Initial Food
Population Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia and Fanconi Anemia Undergoing Allogeneic Hematopoiet
Top View
Fludarabine, High-Dose Cytarabine and Idarubicin-Based
Acronyms for Oncology Regimens
All-Trans Retinoic Acid and Arsenic Trioxide Resistance of Acute Promyelocytic Leukemia with the Variant STAT5B-RARA Fusion Gene
LYFCR Protocol
Fludarabine Plus Cyclophosphamide Combination: a New Standard for First-Line Therapy in Chronic Lymphocytic Leukaemia
Chemotherapy Drugs
Modifying Chemotherapy for the Older Patient
Subcutaneous Administration of Anticancer Agents
Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
Prognostic Impact of Combined Fludarabine, Treosulfan and Mitoxantrone Resistance Profile in Childhood Acute Myeloid Leukemia
The Inhibitor of Histone Deacetylases Sodium Butyrate Enhances the Cytotoxicity of Mitomycin C
Fludarabine As First Line Therapy for Chronic Lymphocytic Leukaemia
Emetogenic Potential of Antineoplastic Agents
(PDF) Download
NCCN Guidelines for Acute Myeloid Leukemia from the 1.2014 Version Include
Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway Via
Adult Antiemetic Management of Chemotherapy-Induced Nausea
The Immunomodulatory Effects of Arsenic Trioxide in Autoimmunity and Alloreactivity Yishan Ye
Therapeutic Polymeric Nanoparticle Compositions
Pharmaceuticals Utilized in Stem Cell Transplant
A Randomized Trial of the AMLCG
Appropriate Use of Bendamustine in First-Line Therapy of Chronic
Fludara 2 (Fludarabine Phosphate)
Absorption Rate Limit Considerations for Oral Phosphate Prodrugs 849
2713-5, 25 Mitomycin C
Medicare Part C Medical Coverage Policy Oral Anticancer Medications
Fludara (Fludarabine Phosphate)
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
©Ferrata Storti Foundation
A Phase I-II Trial of Fludarabine, Bendamustine and Rituximab (FBR) in Previously Treated Patients with CLL
Influence of Fludarabine on Pharmacokinetics and Pharmacodynamics of Cytarabine: Implications for a Continuous Infusion Schedule1
The Prophylactic Potential of Fludarabine Monophosphate in Graft- Versus-Host Disease After Bone Marrow Transplantation in Murin
Pan-Canadian Oncology Drug Review Final Economic Guidance Report Arsenic Trioxide (Trisenox) for Acute Promyelocytic Leukemia
Fludarabine Phosphate Injection Product Monograph
Fludarabine, Cyclophosphamide and Horse Antithymocyte Globulin Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Tr
A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) 2009-0546
Characteristics of Non-Randomized Studies Using Comparisons with External Controls Submitted for Regulatory Approval in the Us and Europe: a Systematic Review
Induction of Apoptosis and Differentiation By
A Clinical and Pharmacological Study of Arsenic Trioxide in Advanced Multiple Myeloma Patients
The Antimetabolites
Bendamustine Added to Allogeneic Conditioning Improves Long-Term Outcomes in Patients with CLL
389.Full-Text.Pdf
Randomized Trial of Intermediate-Dose Cytarabine in Induction and Consolidation
Nitric Oxide Enhancement of Fludarabine Cytotoxicity for B-CLL Lymphocytes
Novel Homobarringtonie‑Containing Therapy for the Treatment of Patients with Primary Acute Myeloid Leukemia That Are Resistant to Conventional Therapy
(PO-Split) Regimen • CLL –
Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia
203469Orig1s000
DRUG NAME: Fludarabine
Hazardous Drug List
CE SESHP Chemo Agents
Fludarabine and Neurotoxicity in Engineered T-Cell Therapy
Fludarabine Cyclophosphamide Rituximab (FCR) Oral
Signaling the End of Chronic Lymphocytic Leukemia: New Frontline Treatment Strategies
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Sample Page 2